Method for preparing biological chip and prepared biological chip

By forming biotin, avidin and biotinylated probe layers with suitable concentration ratios on the biochip, the problem of low sensitivity of existing biochips is solved, and more efficient analyte detection and Alzheimer's disease are achieved. Tools for early diagnosis.

CN118973620APending Publication Date: 2024-11-15NOVASCOPE BIOCHIPS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028394.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-06-01
Filing Date
2023-02-08
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The sensitivity of existing biochips is low, resulting in inconsistent binding efficiency and reduced density of antibody probes, affecting the number of regions that interact with antigens, and thus reducing the detection effect.

Method used

Biochip preparation method using biotin/agibin/biotinylated probes, using 0.1 to 1μg respectively by forming a biotin coating layer, an avidin coating layer and a biotinylated probe layer on the chip. Biotin of /ml, 0.1 to 100 μg/ml avidin and 1 to 3 μg/ml biotinylated probes form suitable concentration ratios to improve binding efficiency and sensitivity.

Benefits of technology

Significantly improves the sensitivity of biochips, enables detection of target analytes such as Tau peptide and SARS-CoV-2 RNA at lower concentrations, and can detect early Alzheimer's related marker p-Tau217 in plasma , has a high linear range and sensitivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973620A_ABST
    Figure CN118973620A_ABST
Patent Text Reader

Abstract

The invention provides a method for preparing a biological chip and the prepared chip. The preparation method comprises the following steps: coating the chip with a first solution containing biotin, a second solution containing avidin and a third solution containing a biotinylation probe;
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to a method for preparing a biochip, in particular to a method for preparing a biochip with improved sensitivity and a biochip prepared thereby. Background Art

[0002] Chips are formed from integrated circuits (ICs), which are made up of transistors, capacitors, and other electronic components on small, flat sheets of semiconductor material, and are used to process electronic signals for various measurements.

[0003] One of the common transistors used in chips is the metal oxide semiconductor field-effect transistor (MOSFET), which controls the current through an electric field. MOSFET has advantages such as high sensitivity, high specificity and real-time detection.

[0004] Biochips include biological components and chip components. The surface of the biochip needs to be modified to accommodate specific probes for various detection targets.

[0005] (3-aminopropyl)triethoxy silane (APTES) and glutaraldehyde (GA) are the most common modifiers and activators for surface functionalization of chips. APTES is an amine-functionalized organosilane. GA is a dialdehyde containing two aldehyde functional groups. The amine group from APTES can easily react with the aldehyde group from GA. One of the aldehyde groups of GA can react with APTES, and the other aldehyde group can react with the antibody of the probe (Udomsom et al., Coatings (2021), 11, 595).

[0006] Other modifiers such as CPTES and VTES and activators such as gelatin, EDC and NHS can be used in chip surface modification processes (Kujawa et al., Science of the Total Environment 801 (2021) 149647). Triethoxysilylundecanal (TESUD) is an alternative modifier that can replace the two-step method of APTES-GA (Lee et al., Sensors and Actuators B 175 (2012) 201-207).

[0007] Since the biochip is functionalized on its surface, the antibody probe can bind to the chip surface with attached functional groups, and then the analyte is added for detection (Sadighbayan et al., Trends in Analytical Chemistry (2020)).

[0008] However, the number of functional groups carried by individual antibody probes is not the same, which may lead to inconsistent binding efficiency. In addition, the position of antibody probes bound to APTES or GA is random, which will reduce the number of Fab (fragment, antigen binding) regions that interact with antigens and reduce the density of antibody probes (Trilling et al., Analyst (2013)). Biotin / antibiotin affinity system is often used to improve this issue. Although this method can increase the binding efficiency of the probe, the sensitivity is still low.

[0009] Thus, there is a need to prepare biochips with biotin / anti-biotin / biotinylated probes with improved sensitivity. Summary of the invention

[0010] An object of the present invention is to provide a biochip with significantly improved sensitivity.

[0011] To achieve the above-mentioned purpose, the present invention provides a method for preparing a biochip, which comprises the following steps: coating a chip with a first solution containing biotin to form a biotin-coated chip, wherein the biotin in the first solution has a first concentration, and the first concentration ranges from 0.1 to 1 μg / ml; providing a biotin-coated chip and a second solution containing avidin to form an avidin / biotin-coated chip, wherein the avidin in the second solution has a second concentration, and the second concentration ranges from 0.1 to 100 μg / ml; and providing an avidin / biotin-coated chip and a third solution containing a biotinylated probe to form a biochip, wherein the biotinylated probe in the third solution has a third concentration, and the third concentration ranges from 1 to 3 μg / ml.

[0012] In one embodiment, the chip is an extended gate field-effect transistor (EGFET).

[0013] In one embodiment, the first concentration of the biotin in the first solution is 0.1 μg / ml.

[0014] In one embodiment, the second concentration of the avidin in the second solution is 30 μg / ml.

[0015] In one embodiment, the third concentration of the biotinylated probe in the third solution is 1 μg / ml.

[0016] In one embodiment, the first concentration of the biotin in the first solution is 1 μg / ml.

[0017] In one embodiment, the second concentration of the avidin in the second solution is 100 μg / ml.

[0018] In one embodiment, the ratio of the first concentration, the second concentration, and the third concentration is 1:300:10.

[0019] In one embodiment, the biotinylated probe is selected from the group consisting of a biotinylated anti-Porcine reproductive and respiratory syndrome virus (PRRSV) antibody, a biotinylated anti-Tau antibody, and a biotinylated SARS-CoV-2 probe. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1A The image is captured by a conjugate microscope, which shows the fluorescence density of biotin-FITC coated on the chip.

[0021] Figure 1B The image is captured by a conjugate microscope, which shows the fluorescence density of biotin-FITC coated on the chip.

[0022] Figure 2 The image was captured by a confocal microscope, showing the fluorescence intensity of avidin AlexaFluor 488 coated on the chip.

[0023] Figure 3A The image was captured by a confocal microscope, showing the fluorescence density of avidin AlexaFluor 488 on a chip treated with 100 ng / ml biotin-NHS.

[0024] Figure 3B The image was captured by a confocal microscope, showing the fluorescence density of avidin AlexaFluor 488 on a chip treated with 1 μg / ml biotin-NHS.

[0025] Figure 4A The images were captured by a confocal microscope, showing the fluorescence density of the PRRSV probe-FAM on the chip, which was first treated with 100 ng / ml of biotin and then with 30 μg / ml of avidin.

[0026] Figure 4B The images were captured by a confocal microscope, showing the fluorescence density of the PRRSV probe-FAM on the chip, which was first treated with 1 μg / ml biotin and then with 100 μg / ml avidin.

[0027] Figure 5A The graphs show the electrical signals of 1 ng / ml, 1 μg / ml and 30 μg / ml of avidin on the chip, respectively. The chip was treated with 0.1 μg / ml of biotin.

[0028] Figure 5B The graphs show the electrical signals of 0.1 μg / ml, 1 μg / ml, and 3 μg / ml of biotinylated antibody on the chip, respectively. The chip was treated with biotin and avidin.

[0029] Figure 6 The figure is a graph showing the results of demonstrating the concentration range of the Tau peptide on the chip.

[0030] Figure 7 A graph showing the demonstrated results for the range of SARS-CoV-2 RNA concentrations on the chip. DETAILED DESCRIPTION

[0031] In order to help understand the purpose, features and effects of the present application, embodiments and drawings that explain the present application in detail are provided.

[0032] The chip in the present application is an extended gate field-effect transistor (EGFET) for sensing analytes (e.g., biological analytes). The biosensing system can utilize a biodetection layer on a substrate (e.g., a conductive substrate or a sensing surface area), which can be coupled to a field effect transistor (FET). The gate of the field effect transistor can be connected to the substrate having the biodetection layer thereon. The functionalized substrate can include a well-defined area (e.g., a well, a matrix, or a flat area), and the well-defined area can hold a specific predetermined volume of fluid (e.g., a liquid, a colloid) thereon. The external electrode can be immersed in the fluid and can be connected to a power supply that supplies a voltage, which can be a gate voltage or a power supply. The change in charge transfer from the external electrode to the gate electrode of the FET caused by the presence of the target molecule in the biodetection layer will adjust the source characteristic of the FET to the drain characteristic. This adjustment can then be correlated to the concentration of the target analyte (e.g., based on a known correlation obtained due to previous calibration results or similar results) that is present in the detection layer. This biosensing system isolates the sensing electronics from the fluid being sensed and its potentially damaging environment (i.e., the FET components are isolated from the fluid containing the analyte). The system can include an external functionalized substrate that is connected to the gate of the FET. The FET also includes a source and a drain, along with a gate electrode for the insulator and the gate. The external electrode can contact the electrolyte, and a gate voltage is applied to the external electrode. The interaction between the ions present in the electrolyte and the functional groups present on the extended gate substrate causes a change in the surface potential. This change in potential causes a change in the current to the gate of the FET. In turn, the gate current regulates the drain-source current in the FET. The regulation of the drain current due to the presence of biomolecules on the surface of the extended gate makes the FET a biosensor.

[0033] Determine the coating concentration of biotin via confocal microscopy

[0034] EGFETs were treated with the following biotins in phosphate-buffered saline (PBS) for 16 hours to form biotin-coated chips: biotin coupled to 0.1 μg / ml fluorescein isothiocyanate (FITC) (Thermo Scientific, #22030), biotin coupled to 0.5 μg / ml FITC, biotin coupled to 1 μg / ml FITC, and biotin coupled to 10 μg / ml FITC. Then, the fluorescence density was observed using a confocal microscope (TCS SP8 STED, Leica), and the images were taken at Figure 1AHowever, the surface of the biochip is not flat, which makes it difficult to focus. Therefore, the conjugate focus image of the biotin-coated chip treated with 1 μg / ml biotin-FITC was captured again. The results are shown in Figure 1B In the present invention, it is pointed out that there is a strong fluorescence density at the concentrations of 0.1 μg / ml and 1 μg / ml. Considering the material cost, the concentration of biotin coated on the chip was selected to be 0.1 μg / ml.

[0035] Determine the appropriate concentration range of avidin

[0036] EGFETs were treated with the following avidin Alexa Fluor 488 (Thermo Scientific, #A21370) in phosphate buffered saline (PBS) for 10 minutes to form an avidin-coated chip: 0.1 μg / ml avidin Alexa Fluor 488, 1 μg / ml avidin Alexa Fluor 488, 10 μg / ml avidin Alexa Fluor 488, 30 μg / ml avidin Alexa Fluor 488, and 50 μg / ml avidin Alexa Fluor 488. Then, the fluorescence density of the avidin-coated chip was observed using a confocal microscope, and the image was taken at Figure 2 The results are shown in Figure 2 In the figure, it is pointed out that there is a strong fluorescence density at the concentrations of 0.1 μg / ml and 30 μg / ml.

[0037] Then, the EGFET was treated with biotin-NHS (Thermo Scientific, #20217) at a concentration of 0.1 μg / ml to form a biotin-coated chip. Then, the biotin-coated chip was treated with the following avidin Alexa Fluor 488 for 10 minutes to form an avidin / biotin-coated chip: avidin Alexa Fluor 488 at a concentration of 1 μg / ml, avidin Alexa Fluor 488 at a concentration of 30 μg / ml, and avidin Alexa Fluor 488 at a concentration of 100 μg / ml. Then, the fluorescence density of the avidin / biotin-coated chip was observed using a confocal microscope, and the image was Figure 3A 30 μg / ml of avidin is equivalent to 2.7×10 14 Avidin molecules, and 0.1 μg / ml of biotin is equal to 2.4×10 14 biotin molecules, that is, the ratio of avidin molecules to biotin molecules is 1:1. The results show Figure 3A In it is pointed out that after the biotin-coated chip (treated with 0.1 μg / ml of biotin) was treated with the following avidin Alexa Fluor 488 to form an avidin / biotin-coated chip, the avidin / biotin-coated chip had a better fluorescence density when the avidin concentration was 30 μg / ml: avidin Alexa Fluor 488 with a concentration of 1 μg / ml, avidin Alexa Fluor 488 with a concentration of 30 μg / ml, and avidin Alexa Fluor 488 with a concentration of 100 μg / ml. In contrast, after the biotin-coated chip (treated with 1 μg / ml of biotin) was treated with the following avidin Alexa Fluor 488 to form an avidin / biotin-coated chip, the avidin / biotin-coated chip had a better fluorescence density when the avidin concentration was 100 μg / ml: avidin Alexa Fluor 488 at a concentration of 1 μg / ml, avidin Alexa Fluor 488 at a concentration of 30 μg / ml, and avidin Alexa Fluor 488 at a concentration of 100 μg / ml, as shown in FIG. Figure 3B 100 μg / ml of avidin is equivalent to 9×10 14 Avidin molecules, and 1 μg / ml of biotin is equal to 2.4×10 15 Biotin molecules, that is, the ratio of avidin molecules to biotin molecules is 1:26.6. 30μg / ml avidin is equal to 2.7×10 14 Avidin molecules, and 1 μg / ml of biotin is equal to 2.4×10 15 biotin molecules, that is, the ratio of avidin molecules to biotin molecules is 1:88.8. Figure 3B In the experiment, the fluorescence density from 1 μg / ml biotin and 100 μg / ml avidin was better than that from 1 μg / ml biotin and 30 μg / ml avidin.

[0038] Determine the appropriate concentration range for biotinylated probes

[0039] In view of the above experiments, the combination of 0.1 μg / ml biotin and 30 μg / ml avidin and the combination of 1 μg / ml biotin and 100 μg / ml avidin were used in subsequent experiments to determine the optimal concentration of the biotinylated probe.

[0040] The nucleic acid probe was modified to have biotin at the 5' end and fluorescein amidites (FAM) at the 3' end. It was observed that the chip coated with 0.1 μg / ml biotin, 30 μg / ml avidin and then 1 μg / ml PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) probe (SEQ ID NO: 1) had better fluorescence intensity, as shown in FIG4 .

[0041] Demonstrating the concentration range of biotinylated antibodies on the chip

[0042] The concentration conditions obtained above are demonstrated based on the change of electrical signals. The change of electrical signals of the chip coated with 0.1 μg / ml of biotin and 30 μg / ml of avidin was measured at different concentrations of biotinylated anti-PRRSV antibodies (0.1 μg / ml, 1 μg / ml and 3 μg / ml), including PRRSV-142VL (SEQ ID NO: 2) and PRRSV-142HL (SEQ ID NO: 3). The threshold voltage (V th The threshold voltage difference (ΔV th ). When the concentration of avidin increased to 30 μg / ml, ΔV th As shown in Figure 5. When the concentration of avidin increased to 30 μg / ml, ΔV th increased to 6.19. The biotinylated PRRSV probe at 1 μg / ml produced the maximum ΔV th However, when the concentration of biotinylated PRRSV probe was increased to 3 μg / ml, ΔV th It will not decrease but will become unstable.

[0043] Demonstrate the concentration range of the target peptide on the chip

[0044] Biotinylated anti-Tau antibodies were initially used to measure the detectable range of the target peptide to determine the sensitivity and detectable range of pathogens in this biological system. The chip was coated with 0.1 μg / ml of biotin, 30 μg / ml of avidin, and 1 μg / ml of biotinylated anti-Tau antibodies, including Tau-217-123VL (SEQ ID NO: 4) and Tau-217-123VH (SEQ ID NO: 5), and then various concentrations of target peptides (i.e., Tau peptide (SEQID NO: 6)) were added. The results indicated that the lowest detectable concentration of Tau peptide was 1 ag / ml, and the highest detectable concentration of Tau peptide on the chip was 50 pg / ml. Figure 6 shown.

[0045] Demonstrate the concentration range of target nucleic acid on the chip

[0046] The sensitivity of the pathogen detected in this biological system was tested using a biotinylated SARS-CoV-2 probe, which included probe-F (SEQ ID NO: 7), probe-P1 (SEQ ID NO: 8), and probe-R (SEQ ID NO: 9) in a ratio of 1:1:1. The chip was coated with 0.1 μg / ml biotin, 30 μg / ml avidin, and then 1 μg / ml of biotinylated SARS-CoV-2 probe. The initial concentration of SARS-CoV-2 total RNA was 2.68×10 6 TCID50. Then different concentrations of SARS-CoV-2 total RNA were added, 2.68×10 -6 , 2.68×10 -4 , 2.68×10 -2 , 2.68, 2.68×10 2 and 2.68×10 3 TCID50 of SARS-CoV-2 total RNA. The results showed that the sensitivity of the chip for detecting SARS-CoV-2 total RNA reached 10 -6 TCID50 (Ct: 48), and the presence of 10 -6 TCID50 to 10 3 The linear range of TCID50 is as follows: Figure 7 shown.

[0047] In the present application, the preferred concentrations of biotin, avidin, and biotinylated anti-PRRSV antibodies used to coat the chip are 0.1 μg / ml, 30 μg / ml, and 1 μg / ml, respectively. At the same time, the preferred concentration ratio of biotin, avidin, and biotinylated anti-PRRSV antibodies is 1:300:10. In addition, this ratio has also been demonstrated on the chip and can produce the maximum voltage signal value. This ratio can be applied to the detection of p-Tau 217 and SARS-CoV-2.

[0048] Phosphorylated Tau protein in cerebrospinal fluid (CSF) is an important biomarker for Alzheimer's disease (AD) (García-Chamé et al., Biosensors and Bioelectronics 159 (2020)). P-Tau 181, p-Tau 217 and p-Tau 231 are the main biomarkers for AD pathological mechanisms (Leuzy et al., EMBO Mol Med (2022) 14: e14408). For early detection of AD in plasma, P-Tau217 has better performance than P-Tau 181 (Janelidze et al., Nature Communications (2020) 11: 1683). Enzyme-linked immunosorbent assay (ELISA) is the most widely used immunoassay method in biomarker research. However, the relatively low sensitivity leads to missed detection. Alternative analytical methods based on technologies such as electrochemiluminescence (ECL) immunosensors, single-molecule analysis (SIMOA), immunomagnetic reduction assay (IMR) and mass spectrometry (MS) are suitable for plasma Tau protein detection (Park et al., Clin Neurol (2022) 18 (4): 401-409). SIMOA is currently a more sensitive detection method. The lower limit of quantification (LLOQ) of p-Tau217 in plasma obtained by SIMOA analysis is 1.8 pg / ml. The LLOQ of p-Tau217 in plasma obtained by ECL-based immunosensor is 34 pg / ml, and the detection range is 0.1 to 100 ng / ml (Jalili et al., Molecules (2022) 27, 431). The sensitivity of the ELISA kit for p-Tau217 is 1 pg / ml to 80 pg / ml (OmnimAbs.OM641673).

[0049] When comparing all the technologies mentioned in the previous paragraphs, the sensitivity of the biotin / avidin chip system of the present application is 180 times higher than that of the SIMOA system and 340 times higher than that of the ECL-based system. The detection limit (LOD) of the biotin / avidin chip system is 1ag / ml (equal to 0.001fg / ml) and presents a linear range from 10fg / ml to 50000fg / ml. The average concentration of p-Tau217 in normal control plasma is 0.13pg / ml (equal to 130fg / ml) (Barthélemy et al., J. Exp. Med. (2020) Vol. 217 No. 11), and the aforementioned concentration is completely within the detection linear range of the current biotin / avidin chip system. In addition, this system only requires a small amount of plasma for detection, and the operating procedure is relatively easy. Therefore, the present application provides useful methods and tools for detecting p-Tau217 in plasma at an early stage for AD diagnosis.

[0050] For the detection of SARS-CoV-2, real-time PCR is the gold standard method for the qualitative and quantitative detection of viral nucleic acid. However, this method needs to be performed in an accredited laboratory and requires skilled technical experts and a long period before the data can be analyzed. Due to the COVID-19 pandemic, many new detection methods have been developed, such as graphene-FET biosensors and silicon nanowire-based viral spike protein detection.

[0051] The graphene-FET biosensor device was able to detect 16 pfu / ml in culture medium and 2.42×10 2 copies / ml (Sadighbayan et al., Trends in Analytical Chemistry (2020)). It can be estimated that the titer of 0.7 pfu is theoretically equal to 1 TCID50 (Pourianfar et al., Indian J Virol. (2012)). Therefore, 16 pfu / ml is equal to 22.8 TCID50. The detection limit of the current biotin / avidin chip system is 10 -6TCID50 (Ct: 48). The sensitivity is better than that of the graphene-FET biosensor. The biotin / avidin protein chip system of the present application uses nucleic acid as a probe for nucleic acid detection without amplification, which can shorten the detection time and does not require skilled technical experts. When the virus load is very low and still in the incubation period, the biotin / avidin protein chip system of the present application can quickly and accurately detect SARS-CoV-2, allowing SARS-CoV-2 to be monitored early and in real time.

[0052] Although the present invention has been described by way of specific embodiments, it will be apparent to those skilled in the art that various modifications and changes may be made without departing from the scope and spirit of the present invention as set forth in the appended claims.

Claims

1. A method for preparing a biochip, characterized in that: Include: Coating a chip with a first solution containing biotin to form a biotin-coated chip, wherein the biotin in the first solution has a first concentration ranging from 0.1 to 1 μg / ml; Providing a second solution containing avidin to the biotin-coated chip to form an avidin / biotin-coated chip, wherein the avidin in the second solution has a second concentration ranging from 0.1 to 100 μg / ml; and A third solution containing a biotinylated probe is provided to the avidin / biotin coated chip to form the biochip, wherein the biotinylated probe in the third solution has a third concentration ranging from 1 to 3 μg / ml.

2. The method of claim 1, wherein: The chip is an extended gate field effect transistor (EGFET).

3. The method of claim 1, wherein: The first concentration of the biotin in the first solution is 0.1 μg / ml.

4. The method of claim 3, wherein: The second concentration of the avidin in the second solution is 30 μg / ml.

5. The method of claim 4, wherein: The third concentration of the biotinylated probe in the third solution is 1 μg / ml.

6. The method of claim 1, wherein: The first concentration of the biotin in the first solution is 1 μg / ml.

7. The method of claim 6, wherein: The second concentration of the avidin in the second solution is 100 μg / ml.

8. The method of claim 7, wherein: The third concentration of the biotinylated probe in the third solution is 1 μg / ml.

9. The method of claim 1, wherein: The ratio of the first concentration, the second concentration and the third concentration is 1:300:

10.

10. The method of claim 1, wherein: The biotinylated probe is selected from the group consisting of a biotinylated anti-porcine reproductive and respiratory syndrome virus antibody, a biotinylated anti-Tau antibody and a biotinylated SARS-CoV-2 probe.

11. A biochip prepared by a method, characterized in that: The method includes: Coating a chip with a first solution containing biotin to form a biotin-coated chip, wherein the biotin in the first solution has a first concentration ranging from 0.1 to 1 μg / ml; Providing a second solution containing avidin to the biotin-coated chip to form an avidin / biotin-coated chip, wherein the avidin in the second solution has a second concentration ranging from 0.1 to 100 μg / ml; and A third solution containing a biotinylated probe is provided to the avidin / biotin coated chip to form the biochip, wherein the biotinylated probe in the third solution has a third concentration ranging from 1 to 3 μg / ml.

12. The biochip according to claim 11, wherein: The chip is an extended gate field effect transistor (EGFET).

13. The biochip according to claim 11, wherein: The first concentration of the biotin in the first solution is 0.1 μg / ml.

14. The biochip according to claim 13, wherein: The second concentration of the avidin in the second solution is 30 μg / ml.

15. The biochip according to claim 14, wherein: The third concentration of the biotinylated probe in the third solution is 1 μg / ml.

16. The biochip according to claim 11, wherein: The first concentration of the biotin in the first solution is 1 μg / ml.

17. The biochip according to claim 16, wherein: The second concentration of the avidin in the second solution is 100 μg / ml.

18. The biochip according to claim 17, wherein: The third concentration of the biotinylated probe in the third solution is 1 μg / ml.

19. The biochip according to claim 11, wherein: The ratio of the first concentration, the second concentration and the third concentration is 1:300:

10.

20. The biochip according to claim 11, wherein The biotinylated probe is selected from the group consisting of a biotinylated anti-porcine reproductive and respiratory syndrome virus antibody, a biotinylated anti-Tau antibody and a biotinylated SARS-CoV-2 probe.